Validation of a Rapid Screening Tool for Anxiety-depressive Disorders in Children, Adolescents and Young Adults Treated in Oncology. Multicenter Study.
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Aug 5, 2025
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new quick and easy tool to help doctors spot anxiety and depression in people who survived cancer as children. Many childhood cancer survivors can experience emotional difficulties like anxiety or depression even years after treatment. Right now, doctors don’t have a simple way to check for these problems during regular follow-up visits. This study aims to create and validate a short test that oncologists can use regularly to identify who is doing well emotionally and who might need more detailed psychological support.
The study is open to young people and adults who were diagnosed with cancer before age 18, have finished their intensive treatment at least three months ago, and are currently considered cancer-free by their doctor. Participants will need to be covered by social security and able to give informed consent, or have a parent or guardian provide consent if they are minors. Those interested in joining can expect to complete this brief screening during their routine medical visits. This tool could make it easier to support the mental health of childhood cancer survivors by quickly identifying those who might benefit from extra care.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • Patients diagnosed with pediatric cancer before the age of 18,
- • Patient whose intensive treatment had ended at least 3 months prior to inclusion,
- • Patients considered to be in complete remission by the doctor responsible for their treatment,
- • Patient affiliated to or entitled under a social security scheme,
- • Patient having received informed information about the study OR the holder(s) of parental authority having received informed information about the study in the case of minors.
- • Exclusion Criteria
- • Refusal to participate expressed by the patient or minor,
- • Patients whose cancer has relapsed or progressed,
- • Pregnant women, women in labor, breast-feeding mothers,
- • Persons deprived of their liberty, hospitalized without consent, hospitalized for purposes other than those of the research,
- • Adults under legal protection (guardianship) or unable to express their consent.
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grenoble, France
Lyon, France
Tours, France
Saint étienne, France
Rouen, France
Patients applied
Trial Officials
CLAIRE BERGER, MD
Principal Investigator
CHU SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported